Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Targeted Induction Therapy for Stage III Unresectable EGFR Mutant Positive NSCLC: a Single-center, Randomized Controlled Trial

NCT07742332 is registered in ClinicalTrials.gov with Peng Zhang as lead sponsor.

NCT NCT07742332
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07742332 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Targeted Induction Therapy for Stage III Unresectable EGFR Mutant Positive NSCLC: a Single-center, Randomized Controlled Trial
Lead sponsor
Peng Zhang
Phase
Phase 2
Overall status
Recruiting
Start date
November 25, 2025
Completion date
November 25, 2032
Enrollment
160 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chemotherapy, egfr, locally advanced non-small cell lung cancer, nsclc (non-small cell lung cancer), radiotherapy